PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128835
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128835
North America anthrax treatment market is projected to register a CAGR of 4.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
North America Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2029.
Rising prevalence of anthrax infections
Increasing research funding and the development of novel therapies for anthrax treatment
Alembic Pharmaceuticals
Integrated Bio Therapeutics Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
EMERGENT
Sanofi
Elusys Therapeutics
Lupin
Soligenix
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
INDOCO REMEDIES LTD.
Paratek Pharmaceuticals, Inc.
BlueWillow Biologics.
Altimmune
RELATED REPORTS 255